24 -5 (67) 2024 - Zoirov Sh.G., Makhmudova A.D. - STUDY OF THE PREVALENCE, AGE-SEX, AND DEMOGRAPHIC CHARACTERISTICS OF CHRONIC MYELOID LEUKEMIA IN THE REPUBLIC OF UZBEKISTAN

STUDY OF THE PREVALENCE, AGE-SEX, AND DEMOGRAPHIC CHARACTERISTICS OF CHRONIC MYELOID LEUKEMIA IN THE REPUBLIC OF UZBEKISTAN

Zoirov Sh.G. - Republican Specialized Scientific and Practical Medical Hematology Center

Makhmudova A.D. - Republican Specialized Scientific and Practical Medical Hematology Center

Islamov M.S. - Republican Specialized Scientific and Practical Medical Hematology Center

Kazakbaeva H.M. - Republican Specialized Scientific and Practical Medical Hematology Center

Resume

With the introduction of tyrosine kinase inhibitors (TKIs) into the therapy of chronic myeloid leukemia (CML) and the high efficacy of this treatment, the life expectancy of patients has changed. It is expected that the improvement in survival, combined with ongoing incidence, will lead to an increase in the prevalence of CML. However, data on the prevalence of CML remains insufficient. We studied the overall and relative (adjusted for age and sex) survival and assessed the past and current prevalence of CML in Uzbekistan. Data on all patients diagnosed with CML from 2003 to 2022 were extracted from patients' medical records. Results: The incidence of CML from 2004 to 2020 averaged 0.62 per 100,000 population per year. A detailed analysis was conducted for various intervals during this period. In the first 14 years, from 2004 to 2017, this rate averaged 0.55 per 100,000 population per year, while a significant increase in newly diagnosed cases of the disease was observed from 2018 to 2020 (incidence rate of 0.94 per 100,000 population per year).

Keywords: chronic myeloid leukemia (CML), prevalence; incidence.

First page

137

Last page

142

For citation: Zoirov Sh.G., Makhmudova A.D., Islamov M.S., Kazakbaeva H.M. - STUDY OF THE PREVALENCE, AGE-SEX, AND DEMOGRAPHIC CHARACTERISTICS OF CHRONIC MYELOID LEUKEMIA IN THE REPUBLIC OF UZBEKISTAN//New Day in Medicine 5(67)2024 137-142 https://newdayworldmedicine.com/en/article/3758

List of References

1. Рябчикова Н.Р., Сафуанова Г.Ш., Бакиров А.Б., Никуличева В.И. Эпидемиология хронического миелолейкоза в Республике Башкортостан и организация терапии. // Медицинский вестник Башкортостана. 2017;12(69):141-145.
2. Туркина А.Г., Зарицкий А.Ю., Шуваев В.А. и др. Клинические рекомендации по диагностике и лечению хронического миелолейкоза. // Клиническая онкогематология. 2017;10(3): 294-316. https://doi.org/10.21320/ 2500 -2139 -2017-10-3-294-316.
3. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia. // Net. Blood. 2006;108(6):1809-1820. https://doi.org/10.1182/blood-2006-02-005686.
4. Baccarani M., Deininger M.W., Rosti G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. // Blood. 2013;122(6):872-884. https://doi.org/10.1182/blood-2013-05-501569.

   file

   download